Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 VAUGHAN, Ontario — Bausch + Lomb Corporation […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.